In addition to clinical data showing the association of single nucleotide polymorphisms, IL-23 levels and AD, preclinical data demonstrate that IL-23 plays a crucial role in neuroinflammation, plaque formation in AD models and identify anti-IL-23 therapy as a promising new therapeutic approach. Here, IL37 is linked to Alzheimer disease.